Skip to main content

When can I remove the Neulasta Onpro?

Medically reviewed by Melisa Puckey, BPharm. Last updated on July 25, 2024.

Official Answer by Drugs.com

You can remove the Neulasta on-body injector when the Neulasta dose delivery is finished, which is when there has been a long beep and the status light is a solid green with NO flashing, or the status light has switched off.

Neulasta Onpro delivery:

How do you remove the Neulasta Onpro (Neulasta on-body injector)?

The best way to remove the Neulasta on-body injector is to grasp the edge of the adhesive pad and slowly peel the on-body injector away from the skin.
Do NOT grab the on-body injector and try to pull it away from the skin.

Once you have removed the on-body injector it is a good idea to inspect the device for any sign of leakage or if the adhesive is wet, as the device may have malfunctioned. If there is any sign of leakage you may not have received the full amount of Neulasta and a replacement dose may be required, therefore it is important to contact your health care provider immediately.

Related questions

How do I dispose of the Neulasta Onpro?

The Neulasta Onpro should be disposed of in a sharps disposal container as it contains a needle.

Bottom line:

References

Read next

What is the difference between Udenyca and Neulasta?

Udenyca (pegfilgrastim-cbqv) and Neulasta (pegfilgrastim) are both biological drugs containing pegfligrastim.

The US Food and Drug Administration (FDA) has approved Udencya as a biosimilar of Neulasta, which means it is "highly similar to, and has no clinically meaningful differences from" Neulasta - it is just as safe and effective and used in the same way. The two drugs, however, are not interchangeable. Continue reading

What does cbqv stand for in pegfilgrastim?

The “cbqv” suffix is found in the biosimilar name for Udenyca (pegfilgrastim-cbqv), a biologic drug used to prevent neutropenia (a lack of certain white blood cells) caused by receiving chemotherapy. The suffix is used to distinguish its name from the original reference product, in this case Neulasta (pegfilgrastim), which has no suffix. The suffix on biosimilars helps healthcare providers and patients realize the medicine is an approved biosimilar, but the suffix has no specific meaning itself. Continue reading

Related medical questions

Drug information

Related support groups